Our approach focuses on a supportive, ongoing partnership that tracks your progress and guides you every step of the way
A total of 34% of recipients of a 2 mg dose had gastrointestinal symptoms compared with 30.8% of those receiving a 1 mg dose
PMID: 18214303
Barbieri M, Bonafe M, Rizzo MR, Ragno E, Olivieri F, Marchegiani F, Franceschi C, Paolisso G
Second, structural biology: cryo-EM structures of full-length MC4R in complex with heterotrimeric Gs, published in Cell Research in 2021, resolved bremelanotide in the orthosteric site alongside alpha-MSH, afamelanotide and a small-molecule agonist, establishing a conserved binding mode for the peptidic ligands and a distinct activation mechanism for MC4R